Literature DB >> 19320010

Longitudinal diffusion tensor imaging in Huntington's Disease.

Kurt E Weaver1, Todd L Richards, Olivia Liang, Mercy Y Laurino, Ali Samii, Elizabeth H Aylward.   

Abstract

Serial diffusion tensor imaging scans were collected at baseline and 1 year follow-up to investigate the neurodegenerative profile of white matter (WM) in seven individuals with the Huntington's Disease (HD) gene mutation and seven control subjects matched on age and gender. In the HD subjects, but not controls, a significant reduction of fractional anisotropy (FA), a measure of WM integrity, between baseline and followup was evident throughout the brain. In addition, a DTI scalar associated with the stability of axons, axial diffusivity, showed significant longitudinal decreases from year 1 to year 2 in HD subjects, declines that overlapped to greater degree with FA discrepancies than longitudinal increases in radial diffusivity, a DTI variable sensitive to demylinization. These preliminary results provide the first longitudinal DTI evidence of WM degeneration in HD and support the notion that FA abnormalities in HD may be a result of axonal injury or withdrawal. These results suggest that longitudinal FA changes may serve as a neuropathological biomarker in HD.

Entities:  

Mesh:

Year:  2009        PMID: 19320010     DOI: 10.1016/j.expneurol.2008.12.026

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  54 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

Review 3.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 4.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

5.  Key role of nuclear medicine in seeking biomarkers of Huntington's disease.

Authors:  Ferdinando Squitieri; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

6.  Joint reconstruction of white-matter pathways from longitudinal diffusion MRI data with anatomical priors.

Authors:  Anastasia Yendiki; Martin Reuter; Paul Wilkens; H Diana Rosas; Bruce Fischl
Journal:  Neuroimage       Date:  2015-12-21       Impact factor: 6.556

7.  White matter changes in patients with friedreich ataxia after treatment with erythropoietin.

Authors:  Karl Egger; Christian Clemm von Hohenberg; Michael F Schocke; Charles R G Guttmann; Demian Wassermann; Marlene C Wigand; Wolfgang Nachbauer; Christian Kremser; Brigitte Sturm; Barbara Scheiber-Mojdehkar; Marek Kubicki; Martha E Shenton; Sylvia Boesch
Journal:  J Neuroimaging       Date:  2013-09-09       Impact factor: 2.486

Review 8.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

Review 9.  The evolving role of diffusion magnetic resonance imaging in movement disorders.

Authors:  Christopher W Hess; Edward Ofori; Umer Akbar; Michael S Okun; David E Vaillancourt
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

10.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.